What is Summit Therapeutics's licensing agreements — revenue?

Summit Therapeutics (SMMT) reported licensing agreements — revenue of $0 in Q3 2023.

How has Summit Therapeutics's licensing agreements — revenue changed year-over-year?

Summit Therapeutics's licensing agreements — revenue decreased by 100.0% year-over-year, from $220K to $0.

What does licensing agreements — revenue mean?

This metric represents the total revenue recognized from licensing intellectual property or technology to third-party partners. It reflects the company's ability to monetize its research and development pipeline through strategic collaborations.

Summit Therapeutics SMMT Licensing agreements — Revenue

Discontinued — last reported Q3 '23

Similar metrics at other companies

GMLicensing agreements income

$49M-7.1%

BBIOLicense and services revenue — Revenue

$4.42M-94.5%

QCOMLicensing

$1.54B-5.0%

EXELLicense revenues — Total revenues

$56.95M+34.1%

MRNALicensing and royalty revenue — Total Revenue

$0-100%

RKTLicense — Revenue

$42M—

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Summit Therapeutics’s 10-Q, filed November 7, 2023, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's licensing agreements — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's licensing agreements — revenue?: Summit Therapeutics (SMMT) reported licensing agreements — revenue of $0 in Q3 2023.
How has Summit Therapeutics's licensing agreements — revenue changed year-over-year?: Summit Therapeutics's licensing agreements — revenue decreased by 100.0% year-over-year, from $220K to $0.
What does licensing agreements — revenue mean?: This metric represents the total revenue recognized from licensing intellectual property or technology to third-party partners. It reflects the company's ability to monetize its research and development pipeline through strategic collaborations.